XTalks
DECEMBER 10, 2024
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is a growing health concern. In the US, MASH affects an estimated three to six percent of the population. This chronic liver disease results from fat accumulation that leads to liver cell damage and inflammation. It is often associated with obesity, type 2 diabetes and cardiovascular risks.
Bio Pharma Dive
DECEMBER 10, 2024
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 10, 2024
While 88.
Bio Pharma Dive
DECEMBER 10, 2024
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 10, 2024
The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.
Bio Pharma Dive
DECEMBER 10, 2024
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
DECEMBER 10, 2024
New findings presented at international SCWD conference
Pharmaceutical Technology
DECEMBER 10, 2024
The EMA has validated Chiesi Global Rare Diseases and Protalixs submission to update the dosing regimen of pegunigalsidase alfa.
Drug Patent Watch
DECEMBER 10, 2024
Patents play a crucial role in protecting intellectual property and fostering innovation. However, the increasing complexity of patent systems has given rise to a phenomenon known as “patent thickets.” These dense webs of overlapping patent rights can significantly impact innovation, market entry, and competition across various industries and countries.
Pharmaceutical Technology
DECEMBER 10, 2024
An improved price discount and new evidence from Santhera has changed NICEs tune following a recommendation shun earlier this year.
XTalks
DECEMBER 10, 2024
Sanofis pivotal LUNA 3 Phase III study has delivered promising results for rilzabrutinib, marking an important advance for adults living with persistent or chronic immune thrombocytopenia (ITP). ITP is a rare autoimmune disorder that leads to dangerously low platelet counts. In this study, rilzabrutinib, an oral Brutons tyrosine kinase (BTK) inhibitor, demonstrated a durable platelet response in 23 percent of treated patients compared to none on placebo, indicating high statistical significance.
Pharmaceutical Technology
DECEMBER 10, 2024
The US FDA has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for COPD.
Pharmaceutical Technology
DECEMBER 10, 2024
Seres Therapeutics has received US FDA breakthrough therapy designation for its SER-155, aimed at decreasing BSIs.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
DECEMBER 10, 2024
New cell therapy shows potential in treating advanced blood disorder
Fierce Pharma
DECEMBER 10, 2024
Drug Patent Watch
DECEMBER 10, 2024
The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers.
Pharmaceutical Commerce
DECEMBER 10, 2024
A panel uncovers how distribution channels are aligning commercialization efforts.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Commerce
DECEMBER 10, 2024
Conference keynote speech examines the industrys critical developments of 2024 and offers a strategic outlook for next year.
Drug Patent Watch
DECEMBER 10, 2024
Generic drug development is a complex process that involves not only scientific and medical expertise but also adherence to strict legal and ethical standards. Scientific expertise plays a crucial role in ensuring that generic drugs are held to the same standards of quality, safety, and efficacy as their brand-name counterparts. This article will delve into the importance of scientific expertise in generic drug development, highlighting the key areas where scientific knowledge is essential.
Pharmaceutical Commerce
DECEMBER 10, 2024
Our December analysis of the twists and turns in the Drug Supply Chain Security Act is a timely one, as the FDA recently again pushed back the deadline for complying with new mandates on tracking and tracing drugs at the package level.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Drug Patent Watch
DECEMBER 10, 2024
Generic drug development is a complex process that requires a deep understanding of regulatory requirements and guidelines. Regulatory expertise plays a crucial role in ensuring that generic drugs meet the necessary standards for quality, safety, and efficacy. In this article, we will explore the importance of regulatory expertise in generic drug development, highlighting the key challenges and opportunities in this field.
Pharmaceutical Commerce
DECEMBER 10, 2024
Click the title above for a link to open the Pharmaceutical Commerce December 2024 issue in an interactive PDF format.
Drug Patent Watch
DECEMBER 10, 2024
Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies. This article delves into the impact of biosimilars on biologic drug manufacturing technologies, highlighting the challenges, opportunities, and future directions in this field.
Pharmaceutical Commerce
DECEMBER 10, 2024
Access Insights Conference delves into the latest obstacles, while mapping out potential solutions to address them.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
99 
Let's personalize your content